NCT05303467View on ClinicalTrials.gov

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 30, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

June 1, 2026

Conditions
Glioblastoma MultiformeRecurrent Glioblastoma
Interventions
DEVICE

TheraSphere GBM

Single treatment of TheraSphere GBM device

Trial Locations (9)

10075

RECRUITING

Lenox Hill Hospital, New York

21287

WITHDRAWN

Johns Hopkins Interventional Radiology Center, Baltimore

32224

RECRUITING

Mayo Jacksonville, Jacksonville

35294

NOT_YET_RECRUITING

University of Alabama Birmingham, Birmingham

60611

RECRUITING

Northwestern Univerity, Chicago

63130

NOT_YET_RECRUITING

Washington University School of Medicine, St Louis

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

92103

NOT_YET_RECRUITING

University of California San Diego, San Diego

94143

RECRUITING

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT05303467 - A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | Biotech Hunter | Biotech Hunter